CKD-701 vs Surabgene lomparvovec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
CKD-701 · Lucenbies
Marketed by Chong Kun Dang Pharmaceutical
NCT04857177 · Phase 3 · completed
In this randomized, double-blind, active-controlled Phase 3 trial, 312 patients with wet AMD were randomized to CKD-701 or the reference biologic Lucentis (ranibizumab). The proportion of patients avoiding significant vision loss was nearly identical between groups (97.95% vs 98.62%), and the difference fell entirely within the trial's prespecified equivalence margin.
Reported efficacy
The proportion of patients with a decrease in the best-corrected visual acuity (BCVA) score of 15 or fewer letters at 3 months versus baseline. (Baseline to 3 months): Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). (met)
Result source: NCT04857177
Surabgene lomparvovec
Developed by AbbVie and partners
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
Reported efficacy
RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)
Result source: NCT04832724
Results for Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. CKD-701: 0 of 4 rows · Surabgene lomparvovec: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | CKD-701 | Surabgene lomparvovec |
|---|---|---|
| Dropout rate | — | 16.7%Cohort 1a NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results0%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 8.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | — | —Cohort 1a NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results—Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | — | 33.3%Cohort 1a NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results33.3%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 25%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 33.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | — | a intraocular inflammation 66.7% retinal haemorrhage 66.7% visual acuity reduced/impairment 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more resultsconjunctival haemorrhage 50% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 66.7% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100% conjunctival haemorrhage 75% retinal thickening 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 91.7% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7% eye irritation 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
CKD-701
Surabgene lomparvovec
show 4 more results
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CKD-701's landscape · Surabgene lomparvovec's landscape